Avax Techs Inc (AVXT) 0.0045 $AVXT
CorMedix: Strong Sell On Partner Failure, Misleading Data And Paid Stock Promotion, -91% Downside
The Pump Stopper - Seeking Alpha - Mon Jun 29, 10:26AM CDT
I believe CorMedix (NYSEMKT: CRMD ) is one of the most brazen, worthless biotech shells of insider enrichment I have ever seen. Bankruptcy documents show CRMD is based on a 1970s -era catheter product acquired for <$1m cash the last time this...
CRMD: 3.78 (+0.16), FBIO: 3.68 (+0.18), ASMB: 18.55 (+0.67)
Metastatic Melanoma - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/2pb9ww/metastatic) has announced the addition of the "Metastatic Melanoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Melanoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Melanoma and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Melanoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Metastatic Melanoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - Vical Incorporated - Amgen Inc. - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - Genentech, Inc. - MedImmune, LLC - Plexxikon Inc. - Delcath Systems, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Eisai Co., Ltd. - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Celgene Corporation - Bayer AG - Incyte Corporation - Luitpold Pharmaceuticals, Inc. - Merck KGaA - Celldex Therapeutics, Inc. - Momenta Pharmaceuticals, Inc. - AVAX Technologies, Inc. - Oncolytics Biotech Inc. - Antisoma plc - Progen Pharmaceuticals Limited - HanAll Biopharma Co., Ltd. - Provectus Biopharmaceuticals, Inc. - BioAlliance Pharma SA For more information visit http://www.researchandmarkets.com/research/2pb9ww/metastatic
ONCY: 0.58 (+0.03), PFE: 34.36 (+0.50), INCY: 108.33 (+0.22), CLDX: 24.89 (+0.42), AMGN: 154.10 (+2.79), BMY: 69.27 (+1.38), GSK: 42.45 (+0.65), MNTA: 21.76 (+0.49), PVCT: 0.51 (+0.01), VICL: 0.70 (unch), AZN: 66.45 (+1.90), DCTH: 0.84 (unch), NVS: 103.22 (+3.20), CELGZ: 2.15 (+0.14)
CorMedix: Strong Sell On Partner Failure, Misleading Data And Paid Stock Promotion, -91% Downside
The Pump Stopper - Seeking Alpha - Mon Jun 29, 10:26AM CDT
I believe CorMedix (NYSEMKT: CRMD ) is one of the most brazen, worthless biotech shells of insider enrichment I have ever seen. Bankruptcy documents show CRMD is based on a 1970s -era catheter product acquired for <$1m cash the last time this...
CRMD: 3.78 (+0.16), FBIO: 3.68 (+0.18), ASMB: 18.55 (+0.67)
Metastatic Melanoma - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/2pb9ww/metastatic) has announced the addition of the "Metastatic Melanoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Melanoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Melanoma and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Melanoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Metastatic Melanoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - Vical Incorporated - Amgen Inc. - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - Genentech, Inc. - MedImmune, LLC - Plexxikon Inc. - Delcath Systems, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Eisai Co., Ltd. - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Celgene Corporation - Bayer AG - Incyte Corporation - Luitpold Pharmaceuticals, Inc. - Merck KGaA - Celldex Therapeutics, Inc. - Momenta Pharmaceuticals, Inc. - AVAX Technologies, Inc. - Oncolytics Biotech Inc. - Antisoma plc - Progen Pharmaceuticals Limited - HanAll Biopharma Co., Ltd. - Provectus Biopharmaceuticals, Inc. - BioAlliance Pharma SA For more information visit http://www.researchandmarkets.com/research/2pb9ww/metastatic
ONCY: 0.58 (+0.03), PFE: 34.36 (+0.50), INCY: 108.33 (+0.22), CLDX: 24.89 (+0.42), AMGN: 154.10 (+2.79), BMY: 69.27 (+1.38), GSK: 42.45 (+0.65), MNTA: 21.76 (+0.49), PVCT: 0.51 (+0.01), VICL: 0.70 (unch), AZN: 66.45 (+1.90), DCTH: 0.84 (unch), NVS: 103.22 (+3.20), CELGZ: 2.15 (+0.14)
